"RDIF and Khimrar consider it possible to start retail sales of Avifavir only after the availability of the drug is increased as a result of optimizing the prime cost of Avifavir," RIA Novosti reports RDIF.

It is noted that "the receipt of permission and the beginning of the use of" Avifavir "for outpatient admission is scheduled for October."

On May 30, Avifavir received approval from the Russian Ministry of Health.